购物车
全部删除
您的购物车当前为空
别名 替西利单抗, JS004
Tifcemalimab(JS004)是一种靶向BTLA(B and T lymphocyte attenuator)的人源化抗体,可结合BTLA并阻断HVEM-BTLA的相互作用,具有免疫调节和抗肿瘤活性。

为众多的药物研发团队赋能,
让新药发现更简单!
Tifcemalimab(JS004)是一种靶向BTLA(B and T lymphocyte attenuator)的人源化抗体,可结合BTLA并阻断HVEM-BTLA的相互作用,具有免疫调节和抗肿瘤活性。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 1 mg | ¥ 2,480 | 现货 | |
| 5 mg | ¥ 5,860 | 现货 | |
| 10 mg | ¥ 7,890 | 现货 | |
| 25 mg | ¥ 11,700 | 现货 | |
| 50 mg | ¥ 15,800 | 现货 |
Tifcemalimab 相关产品
| 产品描述 | Tifcemalimab (JS004) is a humanised antibody targeting BTLA (B and T lymphocyte attenuator), which binds to BTLA and blocks the interaction between HVEM and BTLA, exhibiting immunomodulatory and antitumour activity. |
| 别名 | 替西利单抗, JS004 |
| CAS No. | 2236068-83-8 |
| 颜色 | Transparent |
| 物理性状 | Liquid |
| 存储 | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
评论内容